Partial Heart Transplant for Congenital Heart Disease
Authors' conclusion
Partial heart transplant appears feasible, safe, and efficacious. All transplanted valves demonstrated growth based on annular and leaflet length measurements.
Study context
- Population
- Patients with irreparable congenital heart valve dysfunction at a single high-volume pediatric cardiac surgery and transplant center in the US, April 2022 to December 20249 analysed for growth
- Participants
- 19 patients
- Outcome
- Efficacy: growth of the transplanted valve annulus and leaflets over time
Methodological detailssingle-centre, Median age at transplant 97 days; 53% male, No patients were excluded or lost to follow-up
- Single-centre
- Median age at transplant 97 days; 53% male
- No patients were excluded or lost to follow-up
Main finding
As reported in the abstract
Valve growth (initial cohort, n = 9) · median follow-up 26 weeks
Annular diameter, aortic valve (median)
7 mm to 14 mm
Annular diameter, pulmonary valve (median)
9 mm to 17 mm
Leaflet length, aortic valve (median)
0.5 mm to 1 mm
Leaflet length, pulmonary valve (median)
0.49 mm to 0.675 mm
Observational data: associations, not effects.
Safety
Reoperation unrelated to the implanted valve
- Patients requiring reoperation unrelated to the implanted valve
- 1
Complications related to immunosuppression
- No significant complications related to immunosuppression observed
Original publication
Partial Heart Transplant for Congenital Heart Disease. JAMA. Published 23 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →